MARKET

AXSM

AXSM

Axsome Therapeut
NASDAQ
140.97
+7.01
+5.23%
After Hours: 142.00 +1.03 +0.73% 17:44 11/10 EST
OPEN
134.60
PREV CLOSE
133.96
HIGH
142.93
LOW
133.87
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
260.19
52 WEEK LOW
123.00
MARKET CAP
7.42B
P/E (TTM)
-46.0581
1D
5D
1M
3M
1Y
5Y
1D
Axsome Therapeutics: Buy Rating Reaffirmed as Strong Execution Narrows Losses; $290 Price Target Unchanged
TipRanks · 1d ago
Weekly Report: what happened at AXSM last week (1102-1106)?
Weekly Report · 1d ago
Axsome Advances Adolescent ADHD Study as Investors Await Solriamfetol Data
TipRanks · 4d ago
Axsome Advances Pediatric ADHD Study as Solriamfetol Trial Recruits
TipRanks · 4d ago
Axsome Advances Solriamfetol Safety Study in Children With ADHD
TipRanks · 4d ago
Axsome Therapeutics Price Target Cut to $272.00/Share From $284.00 by Mizuho
Dow Jones · 6d ago
Axsome Therapeutics Is Maintained at Outperform by Mizuho
Dow Jones · 6d ago
Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272
Benzinga · 6d ago
More
About AXSM
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.

Webull offers Axsome Therapeutics Inc stock information, including NASDAQ: AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.